catherine frenette, m · kwo p, frenette ct, peter j, vainorius m, akushevich l, nelson d, fried m,...

Catherine T. Frenette, MD, FAST, AGAF Scripps Clinic/Scripps Green Hospital

10666 North Torrey Pines Rd. N200

La Jolla, CA 92037

Scripps Clinical Research Services

11025 North Torrey Pines Road, Suite 200

La Jolla, CA 92037

Office 858-554-4310

Fax 858-554-3009

Cell 858-699-0662

[email protected]

Positions

Current Appointment Department of Organ Transplantation

Scripps Green Hospital, La Jolla, California

2012-present

Medical Director of Liver Transplantation

Scripps MD Anderson Cancer Center

Director, Liver and Hepatocellular Cancer Program

2018-present

Committee Memberships

Clinical Competency Committee, 2015-present

Scripps Physician Well Being Committee, 2018-present

SCMG Chair/Board of Directors Selection and

Evaluation Committee, 2019-present

Scripps Green Hospital Credentialing Committee,

2019-present

Consulting Appointments Scripps Memorial Hospital, San Diego, California

2014-present

Family Health Centers of San Diego, San Diego, California

Consulting Hepatologist

2017-present

Previous Appointments Department of Medicine

Division of Hepatology

The Methodist Hospital, Houston, Texas

2011-2012

Medical Director of Liver Transplantation

Director, Hepatocellular Carcinoma Program

Assistant Professor of Medicine, Weill Cornell Medical College

2011-2012

mailto:[email protected]


Transplant Medical Staff Quality Management

Committee

Business Practices Committee

Grand Rounds Planning Committee

Kindred Hospital, Houston, Texas

Consulting Hepatologist

2011-2012

Barry S. Levin Department of Transplantation

Division of Hepatology

California Pacific Medical Center, San Francisco, California

2007-2011

Associate Medical Director of Liver Transplantation

2010-2011

Medical Director of the Hepatocellular Carcinoma Program

Medical Director of Las Vegas Outreach Program


Chair, Hepatology Quality Committee

Chair, CME Committee, Hepatology

Critical Care Executive Committee, CPMC

Mortality Review Committee, CPMC

Allied Health Practice Committee, PFCPMC

Protocol Committee, Hepatology

Medical Training

Postgraduate Fellowship Gastroenterology/Hepatology, Scripps Clinic, La Jolla,

California, 2004-2007

Focus on Transplant Hepatology, 2006-2007

Residency Internal Medicine, Scripps Mercy Hospital, San Diego,

California, 2001-2004

Education

Medical MD, Rush Medical College, Chicago, Illinois 1997-2001

Undergraduate Bachelor of Science, Biology, Magna cum Laude

Loyola University, Chicago, Illinois, 1995-1997

Licenses and Certification

Board Certified in Internal Medicine 2004-present

Board Certified in Gastroenterology/Hepatology 2007-present

Certificate of Added Qualification in Transplant Hepatology

2010-present

State License in California 2002-present

State License in Nevada 2007-present

State License in Texas 2010-2012

Professional Affiliations

American Gastroenterology Association

Fellow, American Gastroenterology Association,

awarded 2017

American College of Gastroenterology

American Association for the Study of Liver Diseases

Member, Clinical Research Committee 2006-2007

Member, Hepatobiliary Neoplasia Special Interest Group

Member, Portal Hypertension Special Interest Group

Mentor, AASLD Emerging Liver Scholars Program, 2017

American Society of Transplantation

Liver and Intestinal Community of Practice

Public Policy/Advocacy Subcommittee, 2014-present

Education Subcommittee, 2016-present

Fellow, American Society of Transplantation, awarded 2016

European Association for the Study of the Liver

The Transplantation Society

International Liver Cancer Association

International Liver Transplant Society

Chronic Liver Disease Foundation

Cirrhosis Steering Committee, 2017-present

American Liver Foundation

Medical Advisory Committee Pacific Coast Division,

2016-present

National Medical Advisory Committee Executive Committee,

2018-present

Vice-Chair, Medical Advisory Committee Pacific Coast

Division, 2018-2019

Chair, Medical Advisory Committee Pacific Coast Division,

2020-present

Course Director, ALF Pacific Coast Division Academic

Debates, 2018-present

Member, Scripps Physician Leadership Academy

Northern California Society of Clinical Gastroenterology

Board Member, 2008

Membership Director, 2009

Program Director, 2010

HCC Connect

ALTA Study Publications and Presentations Committee

Association of Community Cancer Centers

Multidisciplinary Hepatocellular Carcinoma Care Medical

Advisory Committee, 2019-present

Publications

Frankul L, Frenette C. Spotlight on impactful research: utilization of aspirin and statin in

management of coronary artery disease in patients with cirrhosis undergoing liver transplant

evaluation. Clin Liver Dis 2019 in press.

Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, Salgia R, Seetharam A, Sharma

P, Sherman C, Tsoulfas G, Yao FY. Liver transplantation for hepatocellular carcinoma:

Management after the transplant. Am J Transplant 2020 Feb;20(2):333-347. PMID 31710773

Fakhreddine A, Frenette C. A cautionary report of doxycycline-induced autoimmune hepatitis.

Hepatology 2019 Nov 7, Epub ahead of print, PMID 31698502

Bi X, Deising A, Frenette C. Acute liver failure from exertional heatstroke can result in excellent

long-term survival with liver transplantation. Hepatology 2019 Sep 11, Epub ahead of print, PMID

31509612

Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG. A practical guideline for hepatocellular

carcinoma screening in patients at risk. Mayo Clin Proc Innov Qual Outcomes 2019 Jul 11;3(3):302-

310. PMID 31485568

Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S,

Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou

JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, Dhanasekaran R,

Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R,

Parikh ND, Murphy CC. Direct-acting antiviral therapy for hepatitis C virus infection Is

associated with increased survival in patients with a history of hepatocellular carcinoma.

Gastroenterology 2019 Nov;157(5):1253-1263.e2. PMID 31374215

Rich NE, Yang JD, Perumalswami PV, Alkhouri N, Jackson W, Parikh ND, Mehta N, Salgia R,

Duarte-Rojo A, Kulik L, Rakoski M, Said A, Oloruntoba O, Ioannou GN, Hoteit MA, Moon AM,

Rangnekar AS, Eswaran SL, Zheng E, Jou JH, Hanje J, Pillai A, Hernaez R, Wong R, Scaglione S,

Samant H, Kapuria D, Chandna S, Rosenblatt R, Ajmera V, Frenette CT, Satapathy SK, Mantry P,

Jalal P, John BV, Fix OK, Leise M, Lindenmeyer CC, Flores A, Patel N, Jiang ZG, Latt N,

Dhanasekaran R, Odewole M, Kagan S, Marrero JA, Singal AG. Provider attitudes and practice

patterns for direct-acting antiviral therapy for patients with hepatocellular carcinoma. Clin

Gastroenterol Hepatol 2019 Jul 26. Epub ahead of print, PMID 31357028

Fakhreddine A, Frenette CT, Konijeti G. A practical review of cytomegalovirus in

gastroenterology and hepatology. Gastroenterol Res Pract 2019 Mar 7;2019:6156581. PMID

30984257

Pate J, Gutierrez JA, Frenette CT, Goel A, Kumar S, Manch RA, Mena EA, Pockros PJ, Satapathy

SK, Yiman KY, Gish RG. Practical strategies for pruritis management in the obeticholic acid-

treated PBC patient: proceedings from the 2018 expert panel. BMJ Open Gastroenterol 2019 Feb

1;6(1):e000256. PMID 30815273

Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S,

Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou

JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R,

Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R,

Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram

M, Xie JJ, Murphy CC, Parikh ND. Direct-acting antiviral therapy not associated with recurrence

of hepatocellular carcinoma in a multicenter North American cohort study. Gastroenterology. 2019

May;156(6):1683-1692.e1. PMID 30660729

Ramers CB, Liu J, Frenette CT. Barriers to treatment of hepatitis C in the direct-acting antiviral

era. Curr Treat Options Infect Dis 2019 April; 11:92-102. doi:10.1007/s40506-019-00184-7

Frenette CT. Increasing awareness on racial disparities in liver transplantation for hepatocellular

carcinoma in the United States. Hepatol Commun 2019 Jan 1;3(1):5-7. PMID 30619989

Grandhe S, Lee JA, Chandra A, Marsh C, Frenette CT. Trapped vessel of abdominal pain with

hepatomegaly: a case report. World J Hepatol 2018 Nov 27;10(11):887-891. PMID 30533189

Pan JJ, Bao F, Du E, Skillin C, Frenette CT, Waalen J, Alaparthi L, Goodman ZD, Pockros PJ.

Morphometry confirms fibrosis regression from sustained virologic response to direct-acting-

antivirals for hepatitis C. Hepatol Commun 2018 Sep 21;2(11):1320-1330. PMID 30411079

Mehta G, Rousell S, Burgess G, Morris M, Wright G, McPherson S, Frenette CT, Cave M, Hagerty

DT, Spada A, Jalan R. A placebo-controlled, multicenter, double-blind, Phase 2 randomised trial

of the pan-caspase inhibitor emricasan in patients with acutely decompensated cirrhosis. J Clin

Exp Hepatol 2018 Sep;8(3):224-234. PMID 30302038

Christian-Miller N, Frenette C. Hepatocellular carcinoma pain: impact and management

challenges. J Hepatocell Carcinoma 2018 Jul 19;5:75-80. PMID 30050880

Frenette CT, Morelli G, Shiffman ML, Frederick RT, Rubin RA, Fallon MB, Cheng JT, Cave M,

Khaderi SA, Massoud O, Pyrsopoulos N, Park JS, Robinson JM, Yamashita M, Spada AP, Chan

JL, Hagerty DT . Emricasan for 6 months improves liver function in patients with cirrhosis and

elevated MELD scores. Clin Gastroenterol Hepatol 2019 Mar;17(4):774-783.e4. PMID 29913280

Ahn J, Sundaram V, Ayoub WS, Frenette C, Wong RJ. Hypoalbuminemia is associated with

significantly higher liver transplant waitlist mortality and lower probability of receiving liver

transplant. J Clin Gastroenterol 2018 Nov/Dec;52(10):913-917. PMID 29356783

Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, Roberts JP, Yao FY. Excellent

outcomes of liver transplantation following down staging of hepatocellular carcinoma to within

Milan criteria – a multi-center study. Clin Gastroenterol Hepatol 2018 Jun;16(6):955-965. PMID

29175528

Nhu QM, Du EZ, Kiyani A, Frenette CT. A rare localized nasal CD30+ primary cutaneous T-cell

lymphoma following liver transplantation. BMJ Case Rep 2017 Nov 4;2017. PMID 29103006

Grandhe S, Frenette CT. Occurrence and recurrence of hepatocellular carcinoma after successful

direct-acting antiviral therapy for patients with chronic hepatitis C virus infection. Gastroenterol

Hepatol 2017 Jul;13(7):421-423. PMID 28867970

Frenette CT. The role of regorafenib in hepatocellular carcinoma. Gastroenterol Hepatol 2017 Feb

13(2):122-124. PMID 28450818

Frenette CT. Novel second-line treatments for hepatocellular carcinoma. Clin Adv Hematol Oncol

2016 Dec;14 Suppl 12(12):3-5. PMID 27930616

Abou-Alfa G, Yen C-J, Hsu C-H, O’Donoghue J, Beylergil V, Ruan S, Pandit-Taskar N, Gansukh

B, Lyashchenko S, Ma J, Wan P, Shao Y-Y, Lin Z-Z, Frenette CT, O’Neil B, Schwartz L, Smith-

Jones P, Ohtomo T, Tanaka T, Morikawa H, Maki Y, Ohishi N, Chen Y-C, Agajanov T, Boisserie F,

De Laurenzio L, Lee R, Larson S, Cheng A, Carrasquilo J. Phase Ib study of codrituzumab in

combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma.

Cancer Chemother Pharmacol 2017 Feb;79(2):421-429. PMID 28120036

Nhu QM, Knowles HJ, Pockros PJ, Frenette CT. Pulmonary complications of transcatheter

arterial chemoembolization for hepatocellular carcinoma. World J of Respirol 2016 Nov; 6(3):69-75.

PMID 27035078

Yan M, Ha J, Aguilar M, Liu B, Frenette CT, Bhuket T, Wong RJ. Older patients with

hepatocellular carcinoma more advanced disease, lower rates of treatment, and lower survival. J

Clin Gastroenterol 2017 Apr;51(4):378-383. PMID 27380460

Frenette CT, Lencioni R, Finn RS. Novel second-line treatments for

hepatocellular carcinoma: Discussion. Clin Adv Hematol Oncol. 2016 Dec;14 Suppl

12(12):12-13. PMID: 27930619.

Ahn J, Bhuket T, Mosadeghi S, Frenette CT, Liu B, Wong RJ. End stage liver disease patients with

MELD > 40 have higher waitlist mortality compared to status 1A patients. Hepatology International

2016 Sep;10(5):838-46.. PMID 27221700

Frenette CT. Surveillance for hepatocellular carcinoma. Gastroenterol Hepatol (N Y). 2016

Jun;12(6):394-6. PMID 27493599

Frenette CT. Surveillance for hepatocellular carcinoma. Clin Adv Hematol Oncol. 2016 Jun;

14(6):407-9. PMID 27379808

Curry MP, O’Leary JG, Bzowej N, Muir AL, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E,

Flamm SL, Schiano T, Teperman L, Fontana R, Schiff E, Fried M, Doehle B, An D, McNally J,

Osinusi A, Brainard DM, McHutchinson JG, Brown RS Jr, Charlton Ml, ASTRAL-4 Investigators.

Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015

Dec 31; 373(27):2618-28. PMID 26569658

Nhu QM, Knowles HJ, Pockros PJ, Frenette CT. An unexpected pulmonary complication

following transcatheter arterial chemoembolization of a small hepatocellular carcinoma. J Clinical

Gastroenterol 2016; 50(6):524-5. PMID 27035078

Brown RS, O’Leary JG, Reddy KR, Kuo A, Morelli GJ, Burton JR, Stravitz RT, Durand C, Di

Bisceglie AM, Kwo P, Frenette CT, Stewart TG, Nelson DR, Friend MW, Terrault NA, HCV-

TARGET Study Group. Inteferon-free therapy for genotype 1 hepatitis C in liver transplant

recipients: real world experience from HCV-TARGET. Liver Transpl 2016 Jan; 22(1):24-33. PMID

26519873

Ha J, Yan M, Aguilar M, Tana M, Liu B, Frenette CT, Bhuket T, Wong R. Race/ethnicity-specific

disparities in hepatocellular carcinoma stage at diagnosis and its impact on receipt of curative

therapies. J Clinical Gastroenterol 2016 May-Jun;50(5):423-30. PMID 26583267

Bhangoo MS, Karnani DR, Hein PN, Giap H, Knowles H, Issa C, Steuterman S, Pockros P,

Frenette CT. Radioembolization with Yttrium-90 microspheres for patients with unresectable

hepatocellular carcinoma. J Gastrointest Oncol 2015; 6(5):469-478. PMID 26487939

Au J, Frenette CT. Management of hepatocellular carcinoma: current status and future directions.

Gut Liver 2015; 9(4):437-448. PMID 26087860

Chiao H, Frenette CT. Solid organ transplantation: little research, big need for patients with

HCV. HCV Next 2014 May/June; 1(3):15-20.

Scherschel A, Minteer WB, Frenette CT. An interesting case of inclusion body myositis after 48-

week interferon treatment for hepatitis C. HCV Next 2014 Mar/Apr; 1(2):8-10.

Crissien AM, Frenette CT. Current management of hepatocellular carcinoma. Gastroenterol

Hepatol 2014 Mar;10(3):153-61. PMID 24829542.

Torres HA, Kaseb A, Mahale P, Miller E, Frenette CT. Telaprevir-containing regimen for

treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver

transplantation: a case series. J Hepatocell Carcinoma 2014 Jul 16;1:109-114. PMID 27508180

Naugler WE, Alsina AE, Frenette CT, Rossaro L, Sellers MT. Building the multidisciplinary team

for management of patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2015 May;

13(5):827-835. PMID 24909910

Brose MS, Frenette CT, Keefe SM, Stein SM. Management of sorafenib-related adverse events: a

clinician’s perspective. Semin Oncol 2014;41(S2):S1-S16. PMID 24576654

Frenette CT, Osorio RC, Stark J, Fok B, Boktour MR, Guy J, Rhee J, Osorio RW. Conventional

TACE and drug eluting bead TACE as locoregional therapy prior to orthotopic liver

transplantation: comparison of explant pathologic response. Transplantation 2014 Oct 15;98(7):781-

7. PMID 24825513

Chiao H, Yang CHE, Frenette CT. Review on liver transplant for hepatocellular carcinoma. Transl

Cancer Res 2013;2(6):472-481.

Au J, Frenette CT. Development of tivantinib as treatment for hepatocellular carcinoma. Journal

Clin Transl Hep 2013;1(1):75-78. PMID 26355274

Frenette CT, Boktour M, Burroughs SG, Kaseb A, Aloia TA, Galati J, Gaber AO, Monsour H Jr,

Ghobrial RM. Pre-transplant utilization of sorafenib is not associated with increased

complications after liver transplantation. Transpl Int 2013 Jul;26(7):734-739. PMID 23701126

Torres HA, Mahale P, Miller ED, Oo TH, Frenette CT, Kaseb AO. Coadministration of telapravir

and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular

carcinoma. World J Hepatol 2013 June 27;5(6):332-335. PMID 23805358

Frenette CT. Current status of bevacizumab for advanced hepatocellular carcinoma. Chin Clin

Oncol 2012; 1:13. PMID 25842071

Monsour HP, Frenette CT, Wyne K. Fatty liver: a link to cardiovascular disease – its natural

history, pathogenesis and pathology. Methodist Debakey Cardiovascular Journal 2012 Jul-Sept;

8(3):21-25. PMID 23227282

Chen WC, Kassi M, Saeed U, Frenette CT. A rare case of amatoxin poisoning in the state of

Texas. Case Reports in Gastroenterol 2012; 6:350-357. PMID 22740810

Chen WC, Frenette C. Hepatic artery pseudoaneurysm: a rare case of gastrointestinal bleeding in

a post liver transplant patient. J Gastrointestin Liver Dis 2012 June; 21(2):125. PMID 22720295

Frenette CT, Gish RG. Targeted systemic therapies for hepatocellular carcinoma: clinical

perspectives, challenges, and implications. World J Gastroenterol 2012 Feb; 18(6):498-506. PMID

22363115

Wong R, Gish RG, Frederick RT, Bzowej NB, Frenette C. The impact of race/ethnicity on the

clinical epidemiology of autoimmune hepatitis. J Clin Gastroenterol 2012 Feb; 46(2):155-61. PMID

21814143

Wong R, Frenette C, Gish RG. Hepatocellular carcinoma: locoregional and targeted therapies.

Gastroenterol Clin North Am 2011 Sept; 40(3):599-610. PMID 21893276

Frenette C, Gish RG. Hepatocellular carcinoma: molecular and genomic guideline for the

clinician. Clin Liver Dis, 2011 May; 15(2):307-21, v11-x. PMID 21689615

Wong R, Frenette C. Updates in the management of hepatocellular carcinoma. Gastroenterol

Hepatol 2011; 7(1):16-24. PMID 21346848

Wong R, Bzowej NB, Frederick RT, Frenette C. Development of hepatocellular carcinoma in

autoimmune hepatitis patients: a case series. Dig Dis Sci 2011; 56(2):578-85. PMID 21046244

Frenette CT, Frederick RT, Gish RG. Clinical management and case reports for the treatment of

hepatocellular carcinoma with sorafenib. J Clin Gastroenterol 2011; 45(8):733-777. PMID 20930642

Wong R, Gish RG, Schilsky M, Frenette C. A clinical assessment of Wilson disease in patients

with concurrent liver disease. J Clin Gastroenterol 2011 Mar; 45(3);267-73. PMID 20535024

Frenette CT, Gish RG. To “be” or not to “be”: that is the question. Am J Gastroenterol 2009 Aug;

104(8):1948-52. PMID 19661938

Frenette CT, Gish RG. Overview of treatment of hepatitis B. Medical Writers’ Circle, The HCV

Advocate, April 2009.

Gish RG, Frenette CT. Review of selected liver cancer abstracts from the AASLD 2008 meeting.

www.natap.org, online publication, December 2008.

Frenette CT, Gish RG. New epidemiology of hepatitis B in the United States. Current Hepatitis

Reports 2008, 8(1):3-9.

Frenette CT, Gish RG. Expert column: screening at-risk individuals for hepatitis B: what do the

guidelines say? Medscape Expert Column, November 24, 2008.

Frenette CT, Kuldau JG, Lane J, Hillebrand DJ, Pockros PJ. Comparison of esophageal capsule

endoscopy and conventional endoscopy for variceal screening. World J Gastroenterol 2008 Jul 28;

14(28):4480-5. PMID 2731273

Frenette CT, Strum WS. Relative rates of missed diagnosis for colonoscopy, barium enema, and

flexible sigmoidoscopy in 379 patients with colorectal cancer. J Gastrointestin Cancer 2008

38(2):148-153. PMID 19089670

Abstracts

Vogel A, Frenette C, Sung M, Daniele B, Baron A, Chan S, Blanc J, Tamai T, Ren M, Lim H,

Palmer D, Takami Y, Kudo M. Baseline liver function and outcomes in the phase III REFLECT

study in patients with unresectable hepatocellular carcinoma.

Poster Presentation, ASCO GI 2020 Gastrointestinal Cancer

Symposium, January 2020.

http://www.natap.org/

Lim H, Merle P, Finn RS, Frenette C, Masi G, Ikeda G, Zebger-Gong H, Fiala-Buskies S, Ozgurdal

K, Kudo M, Qin S. Regorafenib in patients with unresectable hepatocellular carcinoma in routine

clinical practice: interim analysis of the prospective, observational REFINE trial.

Poster Presentation, ASCO GI 2020 Gastrointestinal Cancer

Symposium, January 2020.

Jo J, Boike J, Goel A, Kwong A, Devuni D, Wang C, Serper M, Jones L, Sharma R, Verna E, Shor J,

German M, Hristov A, Lee A, Spengler E, Koteish A, Sehmbey G, Seetharam A, John N, Patel Y,

Kappus M, Couri T, Slagia R, Nhu Q, Frenette C, Lai J, VanWagner L. Donation after cardiac

death liver transplant has no impacy on renal injury or renal failure in recipients of advanced

age.

Oral Presentation, The Liver Meeting, American Association for

the Study of Liver Diseases, November 2019.

Singal A, Rich N, Mehta N, Branch A, Pillar A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J,

Said A, Feld J, John B, Frenette C, Mantry P, Rangnekar A, Oloruntoba O, Leise M, Jou J,

Bhamidimarri K, Kulik L, Ioannou G, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo

A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy S, Parikh N, Murphy C. Direct-acting antiviral

therapy is associated with improved survival in patients with a history of hepatocellular

carcinoma: a multicenter North American cohort study.



Kwong A, Devuni D, Wang C, Boike J, Jo J, VanWagner L, Serper M, Jones L, Sharma R, Verna E,

Shor J, German M, Hristov A, Lee A, Spengler E, Koteish A, Sehmbey G, Seetharam A, John N,

Patel Y, Kappus M, Couri T, Paul S, Salgia R, Nhu Q, Frenette C, Lai J, Goel A, and REALT

Consortium. Acceptable liver transplant outcomes among older recipients with HCC despite

higher-risk features on explant in a large multicenter US cohort (REALT).



Baquerizo A, Vavinskaya V, Rojas A, Mhoyan A, Romero-Gomez M, Sher L, Madani B, Fisher J,

Schaffer R, Frenette C, Marsh C. Intratumoral expression of PD-1/PD-L1 immune checkpoint in

patients with hepatocellular carcinoma.

Poster Presentation, The Liver Meeting, American Association

for the Study of Liver Diseases, November 2019.

Kwong A, Devuni D, Wang C, Boike J, Jo J, VanWagner L, Serper M, Jones L, Sharma R, Verna E,

Shor J, German M, Hristov A, Lee A, Spengler E, Koteish A, Sehmbey G, Seetharam A, John N,

Patel Y, Kappus M, Couri T, Paul S, Salgia R, Nhu Q, Frenette C, Lai J, Goel A, and REALT

Consortium. Outcomes of liver transplantation among older recipients with NASH in a large

multicenter US cohort (REALT).



Mehta N, Guy J, Frenette C, Tabrizian P, Hoteit M, Dhanasekaran R, Dodge J, Holzner L, Frankul

L, Florman S, Parikh N, Yao F. Prospective multi-regional study of down-staging of

hepatocellular carcinoma to within Milan Criteria before liver transplantation.

Oral Presentation, American Transplant Congress, June 2019.

German M, Lee A, Hristov A, Said A, Boike J, Ge J, Jest N, Morelli G, Kolli K, Lai J, Desai A,

Junna S, Pokhrel B, Couri T, Paul S, Frenette C, Christian-Miller N, Verna E, Rahim U, Goel A,

Das A, Pine S, Gregory D, VanWagner L, Spengler E. TIPS effectively treats refractory hepatic

hydrothorax: a multi-center U.S. retrospective study of 1,260 patients.

Oral Presentation, Digestive Disease Week, May 2019.

Oral Presentation, American Transplant Congress, June 2019.

Goel A, Kwong A, Devuni D, Wang C, Boike J, Jo J, VanWagner L, Serper M, Jones L, Sharma R,

Verna E, Shor J, German M, Hristov A, Lee A, Spengler E, Koteish A, Sehmbey G, Seetharam A,

John N, Patel Y, Kappus M, Couri T, Salgia R, Nhu Q, Frenette C, Lai J. Evaluation of liver

transplantation among advanced age recipients in a large multicenter U.S. cohort.

Poster Presentation, American Transplant Congress, June 2019.

Singal A, Mehta N, Rich NE, Murphy C, Frenette CT et al. Direct-acting antiviral therapy

significantly reduces early HCC recurrence: a multicenter US cohort study.



Bi X, Bower R, Deising AC, Frenette CT. Acute liver failure from exertional heatstroke can result

in excellent long-term survival with liver transplantation.



Rojas SA, Khasira M, Trambley J, Cavanaugh C, Asmus L, Frenette CT, Ramers CB. Comparing

modern direct-acting antiviral agents in the real-world setting: a single-center, urban,

underserved FQHC experience.



Ramers CB, Rojas SA, Constantino S, Asmus L, Cavanaugh C, Khasira M, Frenette CT.

Eliminating hepatitis C in the medical home: hepatology, GI, and ID collaboration to build

primary care capacity for treatment.



Reddy KR, Curry MP, Frenette CT, Regenstein FG, Schiff ER, Goodman ZD, Robinson JM, Chan

JL, Imperial JC, Hagerty D. Multicenter, double-blind, randomized trial of emricasan in subjects

post liver transplantation with recurrent hepatitis C virus and liver fibrosis or cirrhosis despite

achieving sustained virologic response.



Boike J, Ge J, German M, Jest N, Morelli G, Spengler E, Said A, Lee A, Hristov A, Kolli K, Lai J,

Desai A, Junna S, Pokhrel B, Couri T, Paul S, Frenette CT, Christian-Miller N, Laurito M, Verna E,

Rahim U, Goel A, Das A, Pine S, Gregory D, VanWagner L. Factors associated with transplant-

free survival after transjugular intrahepatic portosystemic shunt placement: a contemporary

multicenter US experience of 1260 patients.



Junna S, Pokhrel B, Boike J, Ge J, German M, Jest N, Morelli G, Spengler E, Said A, Lee A, Hristov

A, Kolli KP, Lai J, Couri T, Paul S, Frenette CT, Christian-Miller N, Laurito M, Verna E, Rahim U,

Goel A, Das A, Pine S, Gregory D, VanWagner L. Mood altering medications do not increase

post-TIPS hepatic encephalopathy in large multi-center cohort.



Bauer M, Harvey A, Frenette CT. Metastatic seeding of cholangiocarcinoma from biliary drain.

Poster Presentation, American College of Gastroenterology

Annual Meeting, October 2018.

Hai F, Frenette CT, Johnson M. Yttrium 90 radioembolization-induced cirrhosis.



Boike J, Ge J, German M, Jest N, Morelli G, Spengler E, Said A, Lee A, Hristov A, Kolli K, Lai J,

Desai A, Junna S, Pokhrel B, Couri T, Paul S, Frenette CT, Christian-Miller N, Laurito M, Verna E,

Rahim U, Goel A, Das A, Pine S, Gregory D, VanWagner L. Contemporary practice patterns and

outcomes after transjugular intrahepatic portosystemic shunt placement: a multicenter US

experience of 1,146 patients.

Oral Presentation, The International Liver Congress, European

Association for the Study of the Liver, April 2018.


Baquerizo A, Krol V, Frenette CT, Skillin C, Mhoyan A, Madani B, Fisher J, Schaffer R, Pockros P,

Marsh C. Intratumoral expression of Tregs predicts prognosis in patients with hepatocellular

carcinoma.


for the Study of Liver Diseases, October 2017.


Harvey A, Speziale AG, Frenette CT. Finding a way: Hepatitis C virus recurrence in a post-liver

transplant patient with multiple treatment failures. Poster Presentation, American College of Gastroenterology


Chandradas S, Waalen J, Frenette CT. Polycystic liver disease patients may not be appropriately

represented by MELD exception policy.

Poster Presentation, American Transplant Congress, May 2017.

Hooper A, Frenette CT. Steroid-free immunosuppression after liver transplant for autoimmune

disease does not result in increased disease recurrence.


Skillin C, Mba M, Madani B, Frenette CT. Effect of hepatitis C (HCV) treatment on rejection

incidence and severity in post-liver transplant patients.


Kardashian A, Madani B, Frenette CT. Re-evaluation of imaging studies in patients with

hepatocellular carcinoma at a transplant center impacts patient care.


Pockros PJ, Crissien-Martinez A, Frenette CT, Skillin C, Bao F, Du E, Pan J, Waalen J. Degree of

liver fibrosis regression predicted by transient elastography after cure of chronic hepatitis C with

direct acting antivirals is overestimated but confirmed by liver biopsy.

Poster Presentation, The International Liver Congress, European


Mehta N, Guy J, Frenette CT, Sarkar M, Dodge JL, Osorio RW, Minteer WM, Roberts JP, Yao FY.

Multicenter study on down-staging of hepatocellular carcinoma for liver transplantation: is

down-staging failure due to the tumor or the long waiting time?



Frenette CT, Morelli G, Shiffman M, Frederick RT, Rubin RA, Fallon M, Robinson J, Yamashita

M, Spada AP, Chan JL, Hagerty DT. Emricasan (IDN-6556) orally for 6 months in patients with

non-alcoholic steatohepatitis (NASH) cirrhosis decreases the progression of MELD score and

improves liver function.



Frenette CT, Morelli G, Shiffman M, Frederick RT, Rubin RA, Fallon M, Robinson J, Yamashita

M, Spada AP, Chan JL, Hagerty DT. Emricasan (IDN-6556) orally for 6 months in patients with

cirrhosis and elevated MELD score improves liver function.



AASLD Presidential Poster of Distinction

Ahn J, Bhuket T, Liu B, Frenette CT, Ayoub W, Wong RJ. Severe hypoalbuminemia and presence

of ascites are associated with significantly higher liver transplant waitlist mortality independent

of MELD-sodium score.



Nhu QM, Frenette CT. Post-transplant CD30-positive cutaneous T-cell lymphoma: a rare isolated

skin complication following liver transplantation.

Poster Presentation, American College of Gastroenterology 81st

Annual Meeting, Las Vegas, NV, October 2016.

Frenette CT, Morelli G, Shiffman M, Frederick RT, Rubin RA, Fallon M, Yamashita M, Spada AP,

Chan JL, Hagerty DT. Emricasan (IDN-6556) orally for three months in patients with cirrhosis

and MELD scores 11-18 improves clinical parameters of cirrhosis in patients with baseline MELD

score ≥15.

Oral Late Breakers, The International Liver Congress, European


Mehta N, Guy J, Frenette CT, Sarkar M, Dodge J, Osorio RW, Minteer WB, Roberts JP, Yao F.

Multicenter study on down-staging of hepatocellular carcinoma for liver transplantation: further

refinements of criteria based on analysis of factors associated with treatment failure.

Oral Plenary Presentation, The Liver Meeting, American

Association for the Study of Liver Diseases, November 2015.

Crissien-Martinez AM, Minteer W, Pan JJ, Frenette CT, Pockros PJ. Regression of advanced

fibrosis or cirrhosis measured by elastography in patients with chronic hepatitis C who achieve

sustained virologic response after treatment for HCV.



Ahn J, Bhuket T, Mosadeghi S, Frenette CT, Liu B, Wong RJ. End stage liver disease patients with

MELD scores over 40 have a significantly higher waitlist mortality and lower probability of

receiving a liver transplant compared to status 1A fulminant hepatic failure patients.



Frenette CT, Harper A, Baquerizo A, Schaffer R, Fisher J, Marsh C. Traveling for a liver

transplant within the U.S. is not driven by geographic disparity of MELD and does not improve

survival.



Frenette CT, Harper A, Baquerizo A, Schaffer R, Fisher J, Marsh C. Traveling for a liver

transplant in the US does not result in a lower match MELD for the majority of patients.



Nhu Q, Knowles H, Pockros PJ, Frenette CT. An unexpected pulmonary complication following

TACE with low-dose doxorubicin-eluting beads and small volume lipiodol for a small HCC.

Poster Presentation, 80th Annual Scientific Meeting of the

American College of Gastroenterology, October 2015.

Frenette CT, Harper A, Schaffer R, Fisher J, Baquerizo A, Marsh C. Regional Variations: Liver

Transplant Tourism within the US.

Oral Presentation, American Transplant Congress, May 2015.

Frenette CT, Harper A, Waalen J, Fisher J, Schaffer R, Baquerizo A, Marsh C. Descriptive analysis

of patients who travel away from home for orthotopic liver transplantation.


O’Leary J, Brown R, Reddy KR, Kuo A, Morelli G, Stravitz RT, Everson GT, Durand C, Vargas H,

Kwo P, Frenette CT, Peter J, Vainorius M, Akushevich L, Nelson D, Fried M, Terrault N. Safety

and efficacy of all oral DAA therapy for genotype 1 HCV post-liver transplant: interval results

from the HCV-TARGET multicenter prospective observational study.

Oral Presentation, American Transplant Congress, May 2015.

Yan M, Ha J, Aguilar M, Liu B, Frenette CT, Chan C, Bhuket T, Wong RJ. Age-specific disparities

in hepatocellular carcinoma (HCC) outcomes: older patients with HCC have lower rates of HCC

treatment and lower overall survival despite earlier staged disease at presentation.

Oral Presentation, Digestive Disease Week, May 2015.

Ha J, Yan M, Aguilar M, Tana M, Liu B, Frenette CT, Bhuket T, Wong RJ. Asians with

hepatocellular carcinoma (HCC) have earlier staged disease at diagnosis and higher treatment

rates whereas blacks with HCC have more advanced disease at diagnosis and lower treatment

rates.

Poster Presentation, Digestive Disease Week, May 2015.

Jalan R, Wright G, McPherson S, Frenette C, Cave M, Morris M, Huyghe M, Burgess G. A

placebo-controlled, multicenter, double-blind, randomized, pharmacokinetic and

pharmacodynamic trial of emricasan (IDN-6556) in subjects with acute-on-chonic liver failure

(ACLF).

Poster Presentation, The 50th International Liver Congress,

European Association for the Study of the Liver, Vienna,

Austria, April 2015.

Brown RS, Reddy KR, O’Leary JG, Kuo A, Morelli G, Stravitz T, Durand C, Di Biseglie AM,

Vargas HE, Kwo P, Frenette CT, Vainorius M, Akeshevich L, Fried MW, Terrault N. Safety and

efficacy of new DAA-based therapy for hepatitis C post-transplant: interval results from the

HCV-TARGET longitudinal, observational study.

Late-Breaking Oral Session, 65th Annual Meeting of the

American Association for the Study of Liver Diseases, November

2014

Mehta N, Guy J, Frenette CT, Sarkar M, Osorio RW, Minteer WB, Roberts JP, Yao F. Multicenter

study of down-staging of hepatocellular carcinoma to within Milan criteria before liver

transplantation.

Oral Plenary Presentation, 65th Annual Meeting of the American

Association for the Study of Liver Diseases, November 2014

Ali R, Carr-Locke DL, Komanduri S, Jahannath SB, Kachaamy T, Sargon P, Frenette CT, Gagneja

H, Howell D, Buxbaum JL, Laurie T, Marsano JG, Gross S. Hemospray for refractory

gastrointestinal bleeding: Initial United States experience.

Poster Presentation, Annual Scientific Meeting of the

American College of Gastroenterology, October 2014

Jhun HY, Monsour HP, Boktour MR, Emad A, Ghobrial RM, Frenette CT. Diastolic dysfunction

is associated with post liver transplant atrial fibrillation.

Poster Presentation, 64th Annual Meeting of the American


Frenette CT, Boktour M, Jhun HY, Bhimaraj A, Estep J, Asham E, Monsour H, Gaber AO,

Ghobrial RM. Excellent liver transplant outcomes in patients with coronary artery disease.

Poster Presentation, American Transplant Congress, May 2013

Asham E, Boktour M, Frenette CT, Monsour H, Suki W, Gaber AO, Ghobrial RM. Effect of

pretransplant renal replacement therapy on liver transplant outcomes.


Boktour M, Jhun HY, Ghobrial RM, Bhimaraj A, Estep J, Gordon Burroughs S, Monsour H,

Frenette CT. Sensitivity of screening echocardiogram to detect pulmonary hypertension in

patients with end stage liver disease undergoing liver transplant evaluation.


Boktour M, Asham E, Frenette CT, Monsour H, Galati J, Heyne K, Weiner M, Gaber AO, Ghobrial

RM. Pre liver transplant locoregional bridging therapy for HCC: efficacy of combined TACE and

RFA versus TACE alone based on explant pathology.


Jhun HY, Frenette CT, Boktour M, Bhimaraj A, Estep J, Monsour H, Ghobrial RM. Increased

mean pulmonary artery pressure on right heart catheterization affects post-OLT complications.

Oral Presentation, Digestive Disease Week, May 2013

Frenette CT, Jhun HY, Monsour H, Bhimaraj A, Cordero-Reyes A, Kassi M, Trevino A,

Trachtenberg B, Torre-Amione G, Estep J. Pulmonary artery systolic pressure by right heart

catheterization offers additive value to the MELD scoring system to predict outcomes in patients

with end-stage liver disease.

Poster Presentation, 48th Annual Meeting of the European

Association for the Study of the Liver, April 2013

Frenette CT, Stark J, Fok B, Boktour MR, Guy J, Osorio RW. Conventional TACE and drug

eluting bead TACE as locoregional therapy prior to orthotopic liver transplantation: comparison

of explant pathologic response.

Poster Presentation, 63rd Annual Meeting of the American


Frenette CT, Stark J, Fok B, Boktour MR, Guy J, Osorio RW. Comparison of conventional TACE

and drug eluting bead TACE in clinical practice: an analysis of 274 patients with hepatocellular

carcinoma.



Frenette CT, Sadhu AR, Gordon Burroughs S, Boktour MR, Monsour HP, Galati JS, Gaber AO,

Ghobrial RM. Impact of preexisting diabetes mellitus on patient outcome after orthotopic liver

transplantation.



Torres HA, Kaseb A, Mahale P, Miller E, Frenette C. Telaprevir containing regimen against

hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver

transplantation – a case series.



Jhun HY, Frenette C, Schwarz M. Phenytoin-induced Autoimmune Hepatitis.

Poster Presentation, 77th Annual Scientific Meeting of the

American College of Gastroenterology, October 2012

Stark J, Fok B, Frenette C, Osorio R, Guy J. Multidisciplinary specialty evaluation results in

higher rates of treatment for hepatocellular carcinoma.

Poster Presentation, International Liver Cancer Association 6th

Annual Meeting, September 2012.

Yu N, Dittmar K, Frenette C, Monsour H, Gordon-Burroughs S, Ghobrial R

Safe percutaneous thermal ablation of inaccessible high dome liver lesions using one-lung

ventilation technique: preliminary experience.

Poster Presentation, World Conference of Interventional

Oncologists, June 2012

Boktour M, Gordon Burroughs S, Monsour H, Frenette C, Galati J, Moore L, Gaber AO, Ghobrial

RM. Excellent Outcomes of Orthotopic Liver Transplantation (OLT) in Recipients with MELD

>40.

Poster Presentation, American Transplant Congress, June 2012

Frenette CT, Boktour M, Gordon Burroughs S, Monsour H, Galati J, Gaber AO, Ghobrial RM.

Rehabilitation and functional recovery after liver transplantation.

Poster Presentation, International Liver Transplantation Society

Annual Meeting, May 2012

Frenette CT, Gordon Burroughs S, Boktour M, Monsour H, Galati J, Ghobrial RM. Orthotopic

liver transplantation in recipients with transjugular intrahepatic portosystemic shunts is

associated with post-transplant sepsis.



Boktour M, Gordon Burroughs S, Frenette C, Monsour H, Galati JS, Khaderi S, Gaber A, Ghobrial

RM. Orthotopic liver transplant in older recipients is associated with excellent outcomes.




Liver transplantation should be beyond UCSF criteria in patients with Hepatocellular carcinoma.

Poster Presentation, ASTS 12th Annual State of the Art Winter

Symposium, January 2012


Need for post-operative rehabilitation does not predict lower one-year survival.



Boktour M, Gordon Burroughs S, Frenette CT, Monsour H, Galati J, Gaber AO, Ghobrial RM.

Outcomes of liver transplantation based on MELD scores and Karnofsky Index.



Boktour M, Frenette CT, Gordon Burroughs S, Monsour H, Galati J, Khaderi S, Gaber AO,

Ghobrial RM. MELD associated with patients discharged to rehab facilities after orthotopic liver

transplant.

Poster Presentation, 62nd Annual Meeting of the American


Frenette CT, Boktour M, Gordon Burroughs S, Monsour H, Galati J, Khaderi S, Gaber AO,

Ghobrial RM. Sorafenib prior to liver transplant does not result in increased surgical

complications.

Poster Presentation, 62nd Annual Meeting of the American


Frenette CT, Al-Sabouni R, Frederick RT, Tuan B, Gish RG, Hisatake G, Osorio RW. Transarterial

chemoembolization for hepatocellular carcinoma in elderly patients.

Oral Presentation, Global Embolization Symposium, May 2010

Malik B, Shaw R, Frenette CT. Metabolic syndrome and risk to progression to hepatocellular

carcinoma in patient with hepatitis C.

Poster Presentation, Digestive Disease Week, May 2009

Singh E, Frenette CT, Strum WS. Screening colonoscopy in the elderly…cease and desist or let

the madness continue?

Oral Presentation, Digestive Disease Week, May 2008

Frenette CT, Pockros PJ. Sclerosing hepatic carcinoma in a hepatitis B carrier.


Annual Meeting, October 2005

Book Chapters

Chandradas S, Skillin CB, Frenette CT, Hepatocellular Carcinoma: Metastatic Disease, In:

Introduction to Cancer Metastasis, First Edition, Elsevier, 2016, in press.

Peer Review/Editorial Status

Editorial Board Member

Journal of Clinical and Translational Hepatology 2013-present

Translational Cancer Research 2013-present

HCV Next 2013-present

World Journal of Hepatology 2014-2020

HCC Monitor 2015-present

Section Editor, Liver/Hepatobiliary Disease

International Journal of Hepatobiliary and Pancreatic Diseases 2012-present

Guest Editor, Translational Cancer Research

Special Issue on Liver Cancer 2013;2(6)

Clinical Care Options, peer review 2007-present

Digestive Diseases and Sciences, peer review 2011-present

World Journal of Gastroenterology, peer review 2011-present

Journal of Gastrointestinal Cancer, peer review 2011-present

Annals of Oncology, peer review 2012-present

Liver Transplantation, peer review 2012-present

The Lancet, peer review 2014-present

American Journal of Gastroenterology, peer review 2015-present

Gastroenterology and Hepatology, peer review 2015-present

Journal of Gastroenterology and Hepatology, peer review 2015-present

Mayo Clinic Proceedings, peer review 2016-present

Blood, peer review 2016-present

Hepatology, peer review 2017-present

American Journal of Transplantation, peer review 2018-present

Invited Speaker

“Liver Transplantation,” High Sierra Critical Care Conference, Reno, NV March 2008

Guest professor, Metabolic Course, University of California San Francisco Medical School, San

Francisco CA, March 2008 and March 2009.

“New Treatments of Hepatocellular Carcinoma,” California Pacific Medical Center Department

of Transplantation Grand Rounds, San Francisco, CA, May 2008.

“Hepatitis C for the Primary Care Provider,” Open Door Clinic, Eureka, CA, July 2008.

“Hepatitis C treatment in Intravenous Drug Users,” Central Valley Hepatitis Summit, Atwater,

CA August 2008.

“Lunch and Learn: Hepatocellular Carcinoma,” Department of Transplantation, California Pacific

Medical Center, San Francisco, CA, August 2008.

“Medical Care of the Cirrhotic Patient,” UMC School of Medicine, Las Vegas, NV, September

2008.

“Hepatocellular Carcinoma: Screening, Diagnosis, and Treatment,” Gastroenterology and

Hepatology Update, Santa Rosa, CA, Berkeley CA, Las Vegas NV, October 2008 and November

2008.

“Medical Care of the Liver Transplant Patient,” Medicine Grand Rounds, Sutter Santa Rosa

Medical Center, Santa Rosa, CA November 2008.

“Patient Care Alternatives: A Holistic Approach,” Southwest Viral Hepatitis Summit, Las Vegas,

NV November 2008.

“AASLD review 2008: Hepatocellular Carcinoma,” 6th Annual San Luis Obispo Liver and GI

Symposium, San Luis Obispo, CA January 2009.

“Overview of Hepatocellular Carcinoma and Liver Tumors,” UMC School of Medicine, Las

Vegas, NV, January 2009.

“Use of Doxorubicin Eluting Beads in the Treatment of Primary and Metastatic Liver Tumors,”

San Francisco, CA, April 2009.

“Transplantation and Wilsons Disease,” Wilsons Disease Symposium, San Francisco, CA, May

2009

“New Treatments of Hepatocellular Carcinoma,” Grand Rounds, Department of

Gastroenterology, California Pacific Medical Center, San Francisco, CA, May 2009.

“Care of the Cirrhotic Patient in the Intensive Care Unit,” Division of Critical Care, Department

of Medicine, California Pacific Medical Center, San Francisco, CA, June 2009.

“Treatment of Primary and Metastatic Liver Cancer,” Medicine Grand Rounds, Novato

Community Hospital, Novato, CA, June 2009.

“Hepatocellular Carcinoma Screening and Management,” Asian Health Services, Oakland, CA,

November 2009.

“Care of Sepsis in Cirrhotic Patients,” Grand Rounds, Department of Transplantation, California

Pacific Medical Center, San Francisco, CA, December 2009.

“Hepatocellular Carcinoma in the Patient with HIV,” East Bay Aids Center, Oakland, CA,

January 2010.

“Hepatocellular Carcinoma: Review and Update,” Grand Rounds, Department of Medicine,

Highland Hospital, Oakland, CA, February 2010.

“Systemic Treatments of Hepatocellular Carcinoma,” Grand Rounds, Department of

Transplantation, University of Texas, San Antonio, TX, March 2010.

“Hepatocellular Carcinoma, Screening and Treatment,” Northern California Society of

Gastroenterology Nurses and Associates 30th Annual Spring Conference, San Francisco, CA,

March 2010.

“Molecular Targeted Therapy in Hepatocellular Carcinoma,” New Advances in the Management

of Hepatocellular Carcinoma, Chronic Liver Disease Foundation Conference, San Jose, CA, May

2010.

“Hepatology Review,” Chronic Liver Disease Foundation, Las Vegas, NV, May 2010.

“Molecular Signaling in Hepatocellular Carcinoma,” Gastroenterology Grand Rounds, California

Pacific Medical Center, San Francisco, CA, August 2010.

“Use of Sorafenib with Locoregional Therapy,” San Francisco, CA, August 2010.

“Schwartz Grand Rounds,” California Pacific Medical Center, San Francisco, CA, September

2010.

“Hepatocellular Carcinoma Screening and Surveillance,” New Advances in the Management of

Hepatocellular Carcinoma, Chronic Liver Disease Foundation Conference, Roseville, CA, October

2010.

“Hepatocellular Carcinoma Current Treatment Options,” New Advances in the Management of

Hepatocellular Carcinoma, Chronic Liver Disease Foundation Conference, Roseville, CA, October

2010.

“Multidisciplinary Treatment of Hepatocellular Carcinoma,” Oakland, CA, November 2010.

“Hepatocellular Carcinoma Screening and Surveillance,” New Advances in the Management of

Hepatocellular Carcinoma, Chronic Liver Disease Foundation Conference, Las Vegas, Nevada,

November 2010.

“Hepatocellular Carcinoma and Nonalcoholic Fatty Liver Disease,” Annual George P. Noon

Conference on The Management of Organ Failure, The Methodist Hospital, Houston, TX,

December 2010.

“Management of Hepatitis B,” Women in Gastroenterology Annual Conference, San Francisco,

CA, December 2010.

“Management of Hepatocellular Carcinoma Pre- and Post-Liver Transplantation,” San Francisco,

CA, December 2010.

“Hepatocellular Carcinoma Update,” GI fellows conference, New York Hospital Flushing, New

York, NY, February 2011.

“Hepatocellular Carcinoma,” Internal Medicine Grand Rounds, Metropolitan Hospital, New

York, NY, February 2011.

“Multidisciplinary Treatment of Hepatocellular Carcinoma,” GI fellows conference, State

University of New York at Downstate, Brooklyn, NY, February 2011.

“Coagulopathy in Chronic Liver Disease,” VI Annual International Conference on Liver Disease

of Columbia and Venezuela, Columbia Hepatology Association, Medellin, Columbia, March

2011.

“Hepatitis E,” VI Annual International Conference on Liver Disease of Columbia and Venezuela,

Columbia Hepatology Association, Medellin, Columbia, March 2011.

“Nonsurgical Treatment of Hepatocellular Carcinoma,” Hepatocellular Carcinoma: How to

Prepare for the New Epidemic Symposium, Houston, TX, March 2011, College Station, TX, May

2011, Austin, TX, November 2011.

“Cases of Liver Cancer: The New Epidemic,” Liver Grand Rounds, University of Texas Medical

Branch at Galveston, Galveston, TX, April 2011.

“Liver Transplantation for Hepatocellular Carcinoma,” Hepatocellular Carcinoma Research

Interest Group, MD Anderson Medical Center, Houston, TX, May 2011.

“Pathophysiology of Cirrhosis and Portal Hypertension,” Surgical Residency Basic Science

Lecture, The Methodist Hospital, Houston, TX, May 2011.

“Update on Hepatocellular Carcinoma,” Department of Medicine Grand Rounds, The Methodist

Hospital, Houston, TX, May 2011.

“Why I Do Liver Biopsy,” Joint Pathology Residency Didactic Series TMH/UT, Department of

Pathology, The Methodist Hospital, Houston, TX, August 2011.

“Drug-Induced Autoimmune Hepatitis,” Gastroenterology Conference, The Methodist Hospital,

Houston, TX, October 2011

“Management of Hepatocellular Carcinoma,” Hepatology/Liver Transplant Conference, Baylor

College of Medicine, St. Luke’s Hospital, Houston, TX, November 2011

“Clinical Advances in the Management of Cirrhotics,” Chronic Liver Disease Foundation,

Houston, TX, November 2011

“Liver Cancer 101,” Annual George P. Noon Conference on The Management of Organ Failure,

The Methodist Hospital, Houston, TX, December 2011

“Viral Hepatitis Following Transplantation,” 2nd Annual AASLD Highlights Conference, Texas

Gulf Coast Gastroenterological Society, Houston, TX, December 2011

“Nonalcoholic Steatohepatitis and Management Plans,” The Methodist Hospital International

Lecture Series, Houston, TX, February 2012

“Liver Transplantation,” Action Stat Nurse Practitioner Boot Camp, Houston, TX, April 2012

“Workup and Evaluation of Abnormal Liver Tests,” Grand Rounds, Memorial Health System of

East Texas, Lufkin, Texas, July 2012.

“Update on Hepatitis C: Liver and Non-Liver Transplant Patients,” 25th Anniversary Annual

Scientific Meeting of the Texas Transplantation Society, Galveston, Texas, July 2012.

“Cirrhosis and Complications” Internal Medicine Residency Program Noon Conference, The

Methodist Hospital, Houston, Texas, August 2012.

“Physical Therapy and the Cirrhotic Patient,” Didactic Teaching Session, J.C. Walter Transplant

Center liver team, The Methodist Hospital, Houston, Texas, August 2012.

“Update on Hepatocellular Carcinoma,” Radiation Oncology Grand Rounds, The Methodist

Hospital, Houston, Texas, August 2012.

“Navigating Hepatocellular Carcinoma: Applying Clinical Trials Data to Patient Care,” Grand

Rounds, Stratton VA Medical Center, Albany, New York, August 2012.

“Liver Cancer 101,” 4th Annual Collaborative Donation & Transplantation: Both Sides of the Coin,

Lifegift Organ Donation Center, Houston, Texas, August 2012.

“Hepatocellular Carcinoma,” Oncology Grand Rounds, The Methodist Hospital, Houston, Texas,

October 2012.

“What Every Gastroenterologist Needs to Know about Liver Transplantation,” San Diego

Gastroenterology Society, San Diego, CA, January 2013.

“Hepatitis C Treatment in Special Populations,” 28th Annual New Treatments in Chronic Liver

Disease, San Diego, CA, March 2013.

“Hepatocellular Carcinoma”, 28th Annual New Treatments in Chronic Liver Disease, San Diego,

CA, March 2013.

“Liver Transplants and More”, Medicine Grand Rounds, Scripps Memorial Hospital, San Diego,

CA, April 2013.

“Hepatocellular Carcinoma: The New Epidemic”, Medicine Grand Rounds, Scripps Memorial

Hospital Encinitas, Encinitas, CA, April 2013.

“Case Reports in Hepatocellular Carcinoma”, St. Jude Gut Club, Fullerton, CA, June 2013.

“Alcohol, Drugs, and Liver Disease”, Medicine Grand Rounds, Scripps Memorial Hospital, San

Diego, CA, July 2013.

“Liver Transplantation”, Medicine Grand Rounds, Scripps Green Hospital, La Jolla, CA,

September 2013.

“Hepatic Encephalopathy”, American Liver Foundation Hepatitis C and Liver Wellness

Symposium, San Diego, CA, September 2013.

“Medical Care of the Patient with Cirrhosis”, Medicine Grand Rounds, Scripps Mercy Hospital,

San Diego, CA, October 2013.

“Hepatitis C Management in the Liver Transplant Candidate”, Meet the Professor Luncheon, 64th

Annual Meeting of the American Association for the Study of Liver Diseases, November 2013.

“Liver Cancer: Multidisciplinary Team as Standard of Care”, Moving Mountains Series,

University of California Davis, Sacramento, CA, February 2014.

“Hepatitis C: End Stage Liver Disease and Hepatocellular Carcinoma”, 29th Annual New

Treatments in Chronic Liver Disease, San Diego, CA, March 2014.

“Hepatocellular Carcinoma”, 29th Annual New Treatments in Chronic Liver Disease, San Diego,

CA, March 2014.

2014 National Hepatitis B & C Training Program and Treatment Update, San Diego, CA, May

2014.

“Hepatitis Hot Topic: Advances in Hepatitis C”, Southern California Society of Gastroenterology

Post-DDW Symposium, Laguna Beach, CA, June 2014.

“Emerging Therapies in Hepatitis C” Southern California Society of Gastroenterology Post-DDW

Symposium Nurses Course, Laguna Beach, CA, June 2014.

“HCV Alliance”, Chronic Liver Disease Foundation, Temecula, CA, August 2014.

Course Director, National End Stage Liver Disease Training Program and Treatment Update, San

Diego, CA, sponsored by Scripps Clinic, September 2013 and August 2014.

“Current Perspectives into the Management of Hepatic Encephalopathy”, Chronic Liver Disease

Foundation CME series, San Diego, CA, October 2014.

“State of the Art Lecture: Recurrent Diseases, Transplantation”, Texas Gulf Coast

Gastroenterological Society 5th Annual Post-AASLD Symposium, Houston, TX, December 2014.

“New Treatments of Hepatocellular Carcinoma”, Ochsner Advances in the Management of

Chronic Liver Disease Conference, New Orleans, LA, January 2015.

“Viral Hepatitis”, Scripps Mercy Medicine Grand Rounds, Scripps Mercy Hospital, San Diego,

CA, February 2015.

“Hepatitis C”, San Diego Gastroenterology Society, San Diego, CA, February 2015.

“Hepatitis C: Pre and Post Liver Transplant”, 30th Annual New Treatments in Chronic Liver


“How to have a Successful Outcome with HCC”, 30th Annual New Treatments in Chronic Liver


Keynote Speaker, “New Treatments for Hepatitis C”, LIVER360 – A Multidisciplinary Approach

to the Treatment of Liver Disease< sponsored by Rush University Medical Center, Chicago, IL,

April 2015.

2015 National Hepatitis B & C Training Program and Treatment Update, San Diego, CA, June

2015.

Course Director, National End Stage Liver Disease Training Program and Treatment Update, San

Diego, CA, sponsored by Scripps Clinic, September 2015.

“Caring for the Transplant Patient in the Era of Direct-Acting Antivirals”, United Network for

Organ Sharing Region V Collaborative, Las Vegas, NV, October 2015.

“State of the Art Lecture: The Present and Future of Transarterial Radiotherapy”, Korea Liver

Cancer Study Group Congress, HCC Management: Balancing Evidences and Experiences, Seoul,

Korea, January 2016.

“Non-alcoholic Fatty Liver Disease”, Scripps Mercy Hospital Grand Rounds, San Diego, CA,

February 2016.

“Hepatocellular Carcinoma Surveillance”, Phoenix Society of Gastroenterology, Phoenix, AZ,

February 2016.

“Liver Transplantation in 2016”, 31st Annual New Treatments in Chronic Liver Disease, San

Diego, CA, March 2016.

“Hepatitis C and Cirrhosis”, County of San Diego Health and Human Services Agency 6th

Annual Communicable Disease Conference, San Diego, CA, May 2016

2016 National Hepatitis B & C Training Program and Treatment Update, San Diego, CA, June

2016.

Co-Course Director, Emerging Therapies for PBC, NASH, and ESLD, An Evidence-Based

Seminar Focused on Chronic Liver Diseases, San Diego, CA, sponsored by SC Liver Research

Consortium and University of Louisville, September 2016.

“Update on Liver Transplantation”, San Diego Gastrointestinal Society, October 2016.

“Hepatitis C: the Era of Direct-Acting Antivirals and Solid Organ Transplantation”, Baylor St.

Luke’s Organ Transplant Grand Rounds, Houston, TX, October 2016.

“Update on Hepatitis C: The Era of Cure”, Scripps Memorial Hospital Grand Rounds, San Diego,

CA, February 2017.

“Managing Cirrhosis: The Essentials”, 5th Annual Intermountain West Hepatology Update, Salt

Lake City, UT, March 2017.

“Liver Rounds: What’s New in Hepatology”, American College of Physicians Annual Meeting,

San Diego, CA, April 2017.

“Hepatitis C: Cirrhosis and Post-Transplant”, 32nd Annual New Treatments in Chronic Liver

Disease, San Diego, CA, April 2017.

“Hepatocellular Carcinoma: Update on Systemic Treatments”, 32nd Annual New Treatments in

Chronic Liver Disease, San Diego, CA, April 2017.

“The Cirrhotic Patient with Variceal Bleeding”, Clinical Symposium, The Hospitalized Cirrhotic,

Evidence-Based Management, Digestive Disease Week, Chicago, IL, May 2017.

“HCC: Locoregional Therapies, Options and Outcomes”, Meet-The-Professor Luncheon,

Digestive Disease Week, Chicago, IL, May 2017.

Co-Course Director, Emerging Therapies for PBC, NASH, ESLD & HCC, An Evidence-Based

Seminar Focused on Chronic Liver Diseases, San Diego, CA, sponsored by SC Liver Research

Consortium and University of Louisville, May 2017.

“Hepatitis Hot Topic: Update in Hepatitis B and Hepatitis C”, Southern California Society of

Gastroenterology Post-DDW Symposium 2017, Dana Point, CA, June 2017.

2017 National Hepatitis B & C Training Program and Treatment Update, San Diego, CA, July

2017.

“Hepatology for the ID Doctor”, Hepatitis C Pre-Meeting Symposium, ID week, San Diego,

October 2017.

“Liver Rounds: What’s New in Hepatology”, Scripps Mercy/Chula Vista Hospital, Medical

Grand Rounds, San Diego, CA, November 2017.

“Liver Disease and Pregnancy”, Southern California Society of Gastroenterology Post-AASLD

Symposium, Laguna Beach, CA, December 2017.

“Complications of Cirrhosis: Improving Long Term Outcomes”, Eisenhower Medical Center

Grand Rounds, Rancho Mirage, CA, February 2018.

“Hepatocellular Carcinoma Treatment Update”, 6th Annual Intermountain West Hepatology

Update, Salt Lake City, UT, February 2018.

“Hepatitis C: Cirrhosis, Hepatocellular Carcinoma, and Post-Transplant”, 33rd Annual New

Treatments in Chronic Liver Disease, San Diego, CA, March 2018. Course Co-Director

“The Incidental Liver Lesion: When to Relax, When to Follow Up, and When to Panic”, 33rd

Annual New Treatments in Chronic Liver Disease, San Diego, CA, March 2018. Course Co-

Director.

“Hepatocellular Carcinoma: Therapy Updates:, AASLD Clinical Hepatology Update 2018,

Austin, TX, May 2018.

“The Nodular Liver in the Older Adult with Heart Disease: Is It Cirrhosis?”, American

Transplant Congress, Seattle, WA, June 2018.

“Cirrhosis: State-of-the-Art Practical Management”, Clinical Symposium Course Organizer and

Moderator, Digestive Disease Week, Washington D.C., June 2018.

“Managing Chronic Liver Disease in Primary Care”, 35th Annual Primary Care Summer

Conference, San Diego, CA, August 2018.

“Routine Care of the Patient with Cirrhosis”, American College of Gastroenterology Hepatology

School Midwest Regional Postgraduate Course, Indianapolis, IN, August 2018.

“Management of Nonalcoholic Fatty Liver Disease”, American College of Gastroenterology

Hepatology School Midwest Regional Postgraduate Course, Indianapolis, IN, August 2018.

“Routine Care of the Patient with Cirrhosis”, Scripps Memorial Hospital Grand Rounds, La Jolla,

CA, September 2018.

“Hepatitis B: To Treat or Not to Treat?” Hepatitis C Pre-Meeting Symposium, ID week, San

Francisco, October 2018.

“Hepatic Encephalopathy”, American College of Gastroenterology Annual Meeting,

Philadelphia, PA, October 2018.


Hepatology School Southern Regional Postgraduate Course, Nashville, TN, November 2018.


School Southern Regional Postgraduate Course, Nashville, TN, November 2018.

“HCC Abstracts from AASLD”, Southern California Society of Gastroenterology Post-AASLD


“Hepatitis B”, Scripps Mercy Hospital Medical Grand Rounds, San Diego, CA, December 2018.

“Diagnosis and Management of Hepatocellular Carcinoma”, American College of

Gastroenterology Western Regional Postgraduate Course, Las Vegas, NV, January 2019.

“What’s New in NAFLD”, American College of Gastroenterology Western Regional Postgraduate

Course, Las Vegas, NV, January 2019.

“Hepatitis C: The Latest Therapeutic Options”, 2019 American College of

Gastroenterology/Florida Gastroenterology Society Annual Spring Symposium, Naples, FL,

March 2019.

“Hepatitis C: Decompensated Cirrhosis, Hepatocellular Carcinoma, and Post-Transplant”, 34th

Annual New Treatments in Chronic Liver Disease, San Diego, CA, March 2019. Course Co-

Director

“What has Changed in Systemic Treatment for Hepatocellular Carcinoma”, 34th Annual New

Treatments in Chronic Liver Disease, San Diego, CA, March 2019. Course Co-Director.

“NAFLD – What to Expect from Drug Trials”, 7th Annual Intermountain West Hepatology

Update, Salt Lake City, UT, March 2019.

“Immunotherapies for HCC: What the Hepatologist Needs to Know”, AASLD Clinical

Hepatology Update, Bellevue WA, June 2019.

“Nonalcoholic Fatty Liver Disease: What to Tell Your Patient”, Scripps Green Hospital Medical

Grand Rounds, La Jolla, CA, June 2019.

“Approach to Liver Disease in IBD”, Scripps New Advances in Inflammatory Bowel Disease 2019

Conference, La Jolla, CA, September 2019.

“Hepatitis B – Overview with Current and New Treatment Options”, Ask the Experts Liver

Wellness Conference, San Diego, CA, September 2019.

“Epidemic of Obesity: NASH and Obesity in the Transplant Candidate”, Scripps Solid Organ

Transplant Workshop, La Jolla, CA, October 2019. Course Co-Director.

“Hepatitis C Positive Donors and Recipients: When to Treat, Impact on Survival, Solid Organ

Transplant”, Scripps Solid Organ Transplant Workshop, La Jolla, CA, October 2019. Course Co-

Director.

“Fatty Liver Disease and Liver Transplantation”, Osher Lifelong Learning Institute, University of

California San Diego, La Jolla, CA, October 2019.


Hepatology School Southern Regional Postgraduate Course, Louisville, KY, December 2019.


School Southern Regional Postgraduate Course, Louisville, KY, December 2019.

“Impact of Pregnancy on the Liver”, American College of Gastroenterology Hepatology School

Southern Regional Postgraduate Course, Louisville, KY, December 2019.

“HCC Abstracts from AASLD”, Southern California Society of Gastroenterology Liver


“Nonalcoholic Fatty Liver Disease: What to Tell your Patient”, Scripps Memorial Grand Rounds,

La Jolla, CA, January 2020.

Honors and Awards

Journal of Clinical and Translational Hepatology, Outstanding Contribution Award, 2017, 2018

American Liver Foundation Physician of the Year, Pacific Coast Division, 2017

Fellow of the American Gastroenterology Association (AGAF), 2017

American Association of the Study of Liver Disease Annual Meeting Poster of Distinction 2016

Fellow of the American Society of Transplantation (FAST), 2016

San Diego Top Docs 2015, 2016, 2017, 2018, 2019

Patient’s Choice Award 2008, 2009, 2010, 2011

Winner, ASGE 11th Annual Young Investigators’ Conference in Digestive Diseases, April 2007.

Comparison of esophageal capsule endoscopy and conventional endoscopy for variceal

screening.

First Place, San Diego Gastroenterology Society Fellows Research Awards, February 2007.

Relative rates of missed diagnosis for colonoscopy, barium enema, and flexible sigmoidoscopy in

379 patients with colorectal cancer.

First Place, San Diego Gastroenterology Society Fellows Research Awards, February 2006.

Comparison of esophageal capsule endoscopy and conventional endoscopy for variceal

screening.

First Place, Jack Gellar Research Awards, Scripps Mercy Hospital, May 2004. Multiple jejunal

perforations in a patient on chronic steroids.

First Place, Jack Gellar Research Awards, Scripps Mercy Hospital, May 2002. Small Bowel

Metastasis of Renal Cell Carcinoma.

First Place, ACP/ABIM Regional Meeting Associates Poster Competition, October 2002. ‘Small

Bowel Metastasis of Renal Cell Carcinoma.’

catherine frenette, m · kwo p, frenette ct, peter j, vainorius m, akushevich l, nelson d, fried m,...

Documents